Qnity develops a quantum-electrochemical device featuring a custom chip with nano-gold silicon electrodes for molecular screening. This platform delivers ultra-sensitive, real-time binding affinity and kinetic analysis for drug discovery across all molecule sizes. The technology enables faster, more precise screening capabilities at attomolar concentrations.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional molecular screening methods often lack the sensitivity and speed required for comprehensive drug discovery and development. This limitation hinders the ability to accurately measure binding affinities and kinetic data in real-time, impacting the efficiency of identifying viable therapeutic candidates across diverse molecule sizes.
Solution
Qnity offers a quantum-sensing chip designed for ultra-sensitive molecular screening, capable of analyzing molecules from small organics to complex biologics. This platform provides real-time binding affinity and kinetic data, accelerating the drug discovery process. By leveraging quantum sensing technology integrated into a custom chip with nano-gold silicon electrodes, Qnity enables high-throughput screening at attomolar concentrations. This approach redefines drug discovery by offering faster, more precise, and accessible molecular analysis.
Target Audience
The primary customers are organizations involved in drug discovery, including pharmaceutical companies, biotechnology firms, and academic research institutions requiring advanced molecular screening capabilities.
Features
- Quantum-sensing chip with integrated nano-gold silicon electrodes for ultra-sensitive molecular detection.
- Real-time measurement of binding affinity and kinetic parameters for molecular interactions.
- Capability to screen both small molecules and large biomolecules (e.g., peptides, proteins).
- High-throughput screening at attomolar concentration levels.
- Custom chip architecture designed for drug discovery and development workflows.